Direxion Daily LLY Bear 1X Shares(ELIS.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Direxion Daily LLY Bear 1X Shares
ELIS.US
News
View More

Eli Lilly (LLY) Valuation Check After Breakthrough Therapy Status For Sofetabart Mipitecan

Eli Lilly (LLY) has received FDA Breakthrough Therapy designation for its candidate sofetabart mipitecan in treating platinum-resistant ovarian cancer, shifting focus back to oncology. The stock has shown volatility with a 1-day return of 2.12% and a 30-day return of 1.25%, but a strong 90-day return of 28.78% and a 1-year return of 36.52%. Currently trading at $1,064.29, it is about 4% below the average analyst price target of $1,189.18, suggesting it may be undervalued. Analysts project significant growth in sales for its tirzepatide franchise, raising questions about future pricing and valuation risks.

Simplywall·
Simplywall·

Sector Update: Health Care Stocks Lower in Afternoon Trading

Health care stocks experienced a slight decline, with the NYSE Health Care Index down 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3%. Capricor Therapeutics (CAPR) shares fell 2.3% following an FDA request for a full clinical study report. Qiagen (QGEN) shares surged 19% amid takeover interest, while Abivax (ABVX) shares rose 0.5% after its CEO dismissed takeover rumors from Eli Lilly (LLY), which saw a 0.2% increase.

fidelity·
fidelity·

Resona Asset Management Co. Ltd. Sells 15,289 Shares of Eli Lilly and Company $LLY

Resona Asset Management Co. Ltd. has reduced its stake in Eli Lilly and Company (NYSE: LLY) by 5.5%, selling 15,289 shares in the third quarter. The firm now holds 263,865 shares, valued at approximately $199.7 million, making it the 14th largest position in its portfolio. Eli Lilly's stock has seen a recent decline of 2.1%, with a current price of $1,065.05. The company reported strong earnings, beating estimates with $7.02 EPS and a revenue of $17.6 billion for the quarter, reflecting a 53.9% year-over-year increase. Additionally, Eli Lilly announced a quarterly dividend increase to $1.73 per share, payable on March 10th.

Market Beat·
Market Beat·

Compounder sues Lilly and Novo for suppressing GLP-1RA competition

Strive Compounding Pharmacy has filed a lawsuit against Eli Lilly and Novo Nordisk, alleging that the companies are suppressing competition in the GLP-1RA market to limit patient access to compounded medications. The lawsuit claims that Lilly and Novo are using their market dominance to undermine compounding pharmacies through exclusive partnerships and their own online pharmacies. Both companies have denied the allegations, asserting that Strive's claims are without merit and that they are committed to patient safety. The case highlights ongoing tensions between the pharmaceutical industry and compounding pharmacies.

Pharmaceutical Technology·
Pharmaceutical Technology·

Why Is Novo Nordisk Stock Up Today? Wegovy Pill Demand Looks Strong

Novo Nordisk's stock rose nearly 5% to $63.50 following strong demand for its oral Wegovy weight-loss pill, which recorded over 18,000 prescriptions in its first week. This performance surpassed Eli Lilly's Zepbound, which had 8,000 prescriptions in its second week. Goldman Sachs issued a Buy rating, citing potential earnings growth. Despite a 24.30% year-to-date gain, the stock is down 18.80% over the past year. Analysts remain mixed on price targets, and upcoming patent cliffs pose challenges. The next earnings report on February 4, 2026, will be crucial for future guidance.

Talkmarkets·
Talkmarkets·
© 2026 Longbridge｜Disclaimer